RAC 2.20% $1.78 race oncology ltd

Ann: Race Strategic Update August 2023, page-500

  1. 5,744 Posts.
    lightbulb Created with Sketch. 1325
    I went to the Melbourne presentation yesterday and although I have always been confident the meeting confirmed that STRONGLY.
    Without a shadow of a doubt we are in good hands really good hand's everything was explaining and a video will be released as it was recorded.
    The team KNOWS we are sitting on a winning product.
    I support the strategic report as it's what's needed to get the best possible partnership. (That's what big pharma needs to see)
    We have funded to last over till late 2024/2025 and non diluted options are being explored to fund other trials that's needed late 2024/2025
    I strongly believe we will get a partnership for AML first they are in contact with potential partners in different stages of talking.
    Let's see what eventuates, I'm glad I went and anyone that needs anything explained or answered call or email the team and get the real message as conspiracy theories, is not helping RAC and the board when they speak to potential partners.
    Best of luck holders GREAT times are coming.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.